Alkermes Pharma Ireland Limited

Stealth Biotherapeutics Inc.

Centrexion Therapeutics Corporation

Alkermes, Inc.

Solace Therapeutics, Inc.

Scott M Duncan

Tarek A Zeidan

Thomas Andrew Wynn

Christopher P Hencken

Carlos N Sanrame

Martin P Redmon

James N Campbell

D Travis Wilson

Kevin Gerald Connors

William Harwick Gruber

Jan Oudenes

Marc W Andersen

John Gillespie, Jr

Sheila L Caira

Ryan J Cahill

John Gillespie

Shiela Caira

Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH.

Crystalline salt forms

Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH.

Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

Prodrugs of fumarates and their use in treating various diseases

The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2'6′-Dmt-Lys-Phe-NH.

Processes for preparing pharmaceutically relevant peptides

Disclosed are crystalline forms of L-Lys(Boc)-Phe-NHand Boc-D-Arg-DMT. The crystalline forms may be used in the synthesis of elamipretide.

Crystalline dipeptides useful in the synthesis of elamipretide

The present invention provides compounds of formula (I), wherein: The invention also provides pharmaceutical compositions and methods for treating neurological diseases, such as multiple sclerosis.

The invention provides capsaicinoid prodrug compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as pain, and in agonizing TRPV1 activity.

Capsaicinoid prodrug compounds and their use in treating medical conditions

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. 

Disclosed herein are methods and compositions for the treatment and/or prevention of ischemia and ischemia-reperfusion injury comprising administration of at least one peptide disclosed herein, or a pharmaceutically acceptable salt thereof.

Therapeutic compositions including peptides and uses thereof

Disclosed are various crystalline salt forms of L-Phe-D-Arg-L-Phe-L-Lys-NH.

Crystalline salt forms of SBT-20

Disclosed are crystalline forms of the bis- and tris-(hydrochloride) salts of D-Arg-Tyr(2,6-DiMe)-Lys-Phe-NH, which is also known as MTP-131.

Growing community of inventors

Bedford, MA, United States of America

Scott M Duncan